1. Home
  2. BIIB
  3. BIIB News

Latest Biogen Inc. (BIIB) News on April 2, 2025

BIIB

MT Newswires

21 hours ago

Organon Acquires Tofidence for Intravenous Infusion in US

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years
BIIB

Simply Wall St.

a day ago

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?
BIIB

Investor's Business Daily

2 days ago

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen
BIIB

BioPharma Dive

5 days ago

Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen

BIIB

MT Newswires

9 days ago

Biogen Signs Lease for New Global HQ in Cambridge, Massachusetts

3 Value Stocks Walking a Fine Line
BIIB

StockStory

9 days ago

3 Value Stocks Walking a Fine Line

Biogen plots new global headquarters in Kendall Square
BIIB

BioPharma Dive

9 days ago

Biogen plots new global headquarters in Kendall Square

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
BIIB

GlobeNewswire

9 days ago

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?
BIIB

Zacks

13 days ago

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
BIIB

StockStory

13 days ago

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In
BIIB

Insider Monkey

14 days ago

Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia
BIIB

Pharmaceutical Technology

15 days ago

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
BIIB

Zacks

19 days ago

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?

Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
BIIB

Zacks

19 days ago

Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
BIIB

Zacks

21 days ago

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
BIIB

BioPharma Dive

21 days ago

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
BIIB

Clinical Trials Arena

21 days ago

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR

BIIB

MT Newswires

22 days ago

Biogen Initiates Dosing of Phase 3 Study of Felzartamab

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB

GlobeNewswire

22 days ago

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion?
BIIB

Investor's Business Daily

a month ago

Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion?

Tariffs Send Investors to Safety of Food, Drug and Utility Stocks
BIIB

The Wall Street Journal

a month ago

Tariffs Send Investors to Safety of Food, Drug and Utility Stocks

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
BIIB

Pharma Voice

a month ago

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

BIIB

MT Newswires

a month ago

Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia

3 Reasons BIIB is Risky and 1 Stock to Buy Instead
BIIB

StockStory

a month ago

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

BIIB

MT Newswires

a month ago

Biogen, Eisai Say EMA Panel Reaffirms Positive Opinion on Lecanemab

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
BIIB

PR Newswire

a month ago

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts
BIIB

Insider Monkey

a month ago

Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
BIIB

Benzinga

a month ago

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
BIIB

Insider Monkey

a month ago

Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
BIIB

Pharmaceutical Technology

a month ago

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative
BIIB

Simply Wall St.

a month ago

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
BIIB

Benzinga

a month ago

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

BIIB

MT Newswires

a month ago

Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating

BIIB

MT Newswires

a month ago

Piper Sandler Adjusts Price Target on Biogen to $135 From $138, Keeps Neutral Rating

BIIB

MT Newswires

a month ago

Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
BIIB

Business Wire

a month ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen buys rights to Stoke’s rare epilepsy drug
BIIB

BioPharma Dive

a month ago

Biogen buys rights to Stoke’s rare epilepsy drug

BIIB

MT Newswires

2 months ago

Guggenheim Cuts Biogen Price Target to $168 From $190

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
BIIB

Benzinga

2 months ago

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

BIIB

MT Newswires

2 months ago

Biogen Still Offering Value, RBC Says

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
BIIB

Zacks

2 months ago

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
BIIB

TipRanks

2 months ago

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
BIIB

BioPharma Dive

2 months ago

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

BIIB

MT Newswires

2 months ago

Truist Securities Adjusts Price Target on Biogen to $210 From $220, Keeps Buy Rating

BIIB

MT Newswires

2 months ago

Scotiabank Adjusts Biogen Price Target to $224 From $244

BIIB

MT Newswires

2 months ago

Wedbush Adjusts Biogen Price Target to $135 From $166

Biogen expects 2025 profit decline despite strong Q4
BIIB

Yahoo Finance Video

2 months ago

Biogen expects 2025 profit decline despite strong Q4

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
BIIB

Benzinga

2 months ago

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

BIIB

MT Newswires

2 months ago

Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
BIIB

Zacks

2 months ago

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
BIIB

StockStory

2 months ago

Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates

BIIB

MT Newswires

2 months ago

Biogen's Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set

Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition
BIIB

Reuters

2 months ago

Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition

Why Investors Might Hammer Biogen Despite Its Earnings Beat
BIIB

Investor's Business Daily

2 months ago

Why Investors Might Hammer Biogen Despite Its Earnings Beat

BIIB

Investing.com

2 months ago

Bernstein starts Biogen at ‘market-perform,’ notes near term uncertainty

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
BIIB

StockStory

2 months ago

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

BIIB

MT Newswires

2 months ago

Bernstein Initiates Biogen at Market Perform With $160 Price Target

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
BIIB

Zacks

2 months ago

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts
BIIB

Insider Monkey

2 months ago

Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts

Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
BIIB

Zacks

2 months ago

Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Genentech eyes lupus market for Gazyva with positive Phase III data readout
BIIB

Pharmaceutical Technology

2 months ago

Genentech eyes lupus market for Gazyva with positive Phase III data readout

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
BIIB

Zacks

2 months ago

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Lilly’s investigational Alzheimer’s to be investigated in prevention trial
BIIB

Clinical Trials Arena

2 months ago

Lilly’s investigational Alzheimer’s to be investigated in prevention trial

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
BIIB

Zacks

2 months ago

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?
BIIB

Insider Monkey

2 months ago

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?

BIIB

MT Newswires

2 months ago

Biogen, Eisai Say EU Panel Set to Discuss Additional Safety Data on Lecanemab

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
BIIB

GlobeNewswire

2 months ago

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
BIIB

Zacks

2 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
BIIB

Zacks

2 months ago

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
BIIB

Zacks

2 months ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

BIIB

MT Newswires

2 months ago

BMO Capital Adjusts Price Target on Biogen to $156 From $164, Keeps Market Perform Rating

BIIB

MT Newswires

2 months ago

Leerink Partners Adjusts Biogen Price Target to $260 From $290, Maintains Outperform Rating

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
BIIB

Zacks

2 months ago

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

Sage rejects Biogen’s $469m takeover bid
BIIB

Pharmaceutical Technology

2 months ago

Sage rejects Biogen’s $469m takeover bid

BIIB

MT Newswires

2 months ago

Citigroup Adjusts Price Target on Biogen to $160 From $190, Maintains Neutral Rating

BIIB

MT Newswires

2 months ago

Sector Update: Health Care Stocks Gain Late Afternoon

BIIB

MT Newswires

2 months ago

Sector Update: Health Care Stocks Gain Monday Afternoon

Sage rebuffs Biogen bid to take it over
BIIB

BioPharma Dive

2 months ago

Sage rebuffs Biogen bid to take it over

BIIB

MT Newswires

2 months ago

Update: Sage Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

BIIB

MT Newswires

2 months ago

SAGE Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
BIIB

Reuters

2 months ago

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Eisai and Biogen’s LEQEMBI sBLA set for Alzheimer’s maintenance dosing
BIIB

Pharmaceutical Technology

2 months ago

Eisai and Biogen’s LEQEMBI sBLA set for Alzheimer’s maintenance dosing

BIIB

MT Newswires

2 months ago

Goldman Sachs Adjusts Price Target on Biogen to $281 From $290, Keeps Buy Rating

BIIB

MT Newswires

2 months ago

Biogen, Eisai Receive US FDA Biologics Approval for Leqembi Dosing

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
BIIB

Reuters

2 months ago

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
BIIB

GlobeNewswire

2 months ago

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
BIIB

Zacks

2 months ago

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug

Biogen’s higher dose Spinraza under review by US and EU regulators
BIIB

Pharmaceutical Technology

2 months ago

Biogen’s higher dose Spinraza under review by US and EU regulators

BIIB

MT Newswires

2 months ago

Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment

BIIB

MT Newswires

2 months ago

Wedbush Cuts Price Target on Biogen to $166 From $187, Keeps Neutral Rating

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
BIIB

GlobeNewswire

2 months ago

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk
BIIB

Yahoo Finance

2 months ago

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk

Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma
BIIB

The Wall Street Journal

2 months ago

Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
BIIB

Zacks

3 months ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Eli Lilly Stock Has Tumbled 22% Since Its August High. Is It A Buy Or A Sell?
BIIB

Investor's Business Daily

3 months ago

Eli Lilly Stock Has Tumbled 22% Since Its August High. Is It A Buy Or A Sell?

At JPM, Biogen CEO tries to take down the deal temperature
BIIB

BioPharma Dive

3 months ago

At JPM, Biogen CEO tries to take down the deal temperature

Federal watchdog cites concerns with FDA’s accelerated approval process
BIIB

BioPharma Dive

3 months ago

Federal watchdog cites concerns with FDA’s accelerated approval process

Biogen CEO sees no burning need for more acquisitions
BIIB

Reuters

3 months ago

Biogen CEO sees no burning need for more acquisitions

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
BIIB

TipRanks

3 months ago

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

Biogen bid for Sage does not change narrative, says BMO Capital
BIIB

TipRanks

3 months ago

Biogen bid for Sage does not change narrative, says BMO Capital

Share on Social Networks: